《阿斯利康AstraZeneca（AZN）2025年第一季度投資者和分析師財報電話會議紀要PPT「LSE」（英文版）（40頁）.pdf》由會員分享，可在線閱讀，更多相關《阿斯利康AstraZeneca（AZN）2025年第一季度投資者和分析師財報電話會議紀要PPT「LSE」（英文版）（40頁）.pdf（40頁珍藏版）》請在三個皮匠報告上搜索。

1、Q1 2025 ResultsConference call and webcast for investors and analysts 29 April 20252Forward-looking statementsThis document contains certain forward-looking statements with respect to the operations,performance and financial condition of the Group,including,among other things,statements about expect

2、ed revenues,margins,earnings per share or other financial or other measures.Although the Group believes its expectations are based on reasonable assumptions,any forward-looking statements,by their very nature,involve risks and uncertainties and may be influenced by factors that could cause actual ou

3、tcomes and results to be materially different from those predicted.The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements.The Group identifies the forward

4、-looking statements by using the words anticipates,believes,expects,intends and similar expressions in such statements.Important factors that could cause actual results to differ materially from those contained in forward-looking statements,certain of which are beyond the Groups control,include,amon

5、g other things:the risk of failure or delay in delivery of pipeline or launch of new medicines;the risk of failure to meet regulatory or ethical requirements for medicine development or approval;the risk of failures or delays in the quality or execution of the Groups commercial strategies;the risk o

6、f pricing,affordability,access and competitive pressures;the risk of failure to maintain supply of compliant,quality medicines;the risk of illegal trade in the Groups medicines;the impact of reliance on third-party goods and services;the risk of failure in information technology or cybersecurity;the

7、 risk of failure of critical processes;the risk of failure to collect and manage data and AI in line with legal and regulatory requirements and strategic objectives;the risk of failure to attract,develop,engage and retain a diverse,talented and capable workforce;the risk of failure to meet our susta

8、inability targets,regulatory requirements and stakeholder expectations with respect to the environment;the risk of the safety and efficacy of marketed medicines being questioned;the risk of adverse outcome of litigation and/or governmental investigations;intellectual property risks related to the Gr

9、oups products;the risk of failure to achieve strategic plans or meet targets or expectations;the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business;the risk of failure in internal control,financial reporting or the occurrence of fraud;the risk of une

10、xpected deterioration in the Groups financial position;the risk of foreign exchange rate movements impacting our financial condition or results of operations;and the impact that global and/or geopolitical events may have or continue to have on these risks,on the Groups ability to continue to mitigat

11、e these risks,and on the Groups operations,financial results or financial condition.Nothing in this document,or any related presentation/webcast,should be construed as a profit forecast.3Q1 2025 ResultsConference call agenda CEO Opening RemarksPascal SoriotChief Executive OfficerFinancial ResultsAra

12、dhana SarinChief Financial OfficerOncology HaematologyDave FredricksonEVP,Oncology Haematology BusinessSusan GalbraithEVP,Oncology Haematology R&DBioPharmaceuticalsRuud DobberEVP,BioPharmaceuticals BusinessSharon BarrEVP,BioPharmaceuticals R&DRare DiseaseMarc DunoyerChief Executive Officer,AlexionCE

13、O Closing Remarks,Q&APascal SoriotChief Executive OfficerCEO Opening RemarksPascal SoriotCHIEF EXECUTIVE OFFICER45Strong commercial and pipeline delivery in Q1 2025Sustained commercial momentum+10%Total Revenue1+21%Core EPS1 13 new approvals in key regions2,3Continued pipeline delivery5 positive Pha

14、se III readoutsKey indication expansion Imfinzi in GC/GEJC and Enhertu in breast,gastric39 NMEs delivered toward ambition of 20 by 2030 with approval of Beyonttra(acoramidis)4All growth rates at CER.1.Growth rates relative to Q1 2024 performance.2.Key regions US,EU,Japan,China.3.Since Q4/FY 2024 res

15、ults.4.Alexion,AstraZeneca Rare Disease has rights to Beyonttra in Japan.Collaboration partners:Daiichi Sankyo(Enhertu).Appendix:Glossary.All growth rates at CER.Appendix:Glossary.6Q1 2025 benefit from broad-based global businessBroad-based,diverse source of Total RevenueQ1 2025|%Total Revenue by ge

16、ographyQ1 2025|%Total Revenue by therapy areaOncology 42%CVRM 24%R&I 15%V&I 2%Other 2%Rare Disease 15%US42%Europe20%Ex-China 16%China13%ERoW 9%Strength across therapy areas Q1 2025|Total Revenue($m)Growth across geographiesQ1 2025|Total Revenue($m)OncologyBioPharmaceuticalsRare DiseaseUSEmerging Mar

17、ketsEuropeERoW+17%+5%1.Proposed EsoBiotec acquisition expected to close in the second quarter of 2025,subject to customary closing conditions and regulatory clearances.Appendix:Glossary.7Investing in transformative technologies and global R&D footprint to support long-term growth ambitionsGlobal pre

18、sence with six strategic R&D centresCambridge,UKGothenburg,SwedenGaithersburg,USBoston,US Kendall Sq.Shanghai,ChinaBeijing,ChinaIn-vivo cell therapyNovel modalities Innovative deliveryProposed acquisition of EsoBiotec1“Off-the-shelf”cell therapy platform Multi-specific biologics with Harbour BioMedM

19、acro-cyclic peptides with SyneronExclusive license for ALT-B4 from Alteogen Subcutaneous formulations of multiple oncology assetsValue-enhancing business development in Q1 2025Key regions supplied by local manufacturing8A growing broad-based global footprintResilient,dual-source supply chain with in

20、vestment in transformative technologiesSdertlje,SwedenBiologics filling capabilitiesRockville,Maryland Next-generation cell therapy manufacturingSingaporeEnd-to-end ADC manufacturingQingdao,ChinaInhaled medicines plant Dublin,IrelandNew API facilityFrederick,Maryland Manufacturing facility for biolo

21、gicsUS sites11production facilities31Santa Monica,CaliforniaNext-generation cell therapy manufacturingWuxi,ChinaNext-wave of small molecule manufacturingExisting site Increasing investmentNew site LegendVast majority of products sold in US are manufactured in USFinancial Results Aradhana SarinCHIEF

22、FINANCIAL OFFICER9Due to rounding,the sum of a number of dollar values and percentages may not agree to totals.Absolute values at actual exchange rates;changes at CER.1.Total operating expense includes distribution,R&D and SG&A expenses.Appendix:Glossary.10Q1 2025 Reported profit and lossQ1 2025$mCE

23、R change%TotalRevenue-Product Sales12,875995-Alliance Revenue639425Product Revenue13,5141099-Collaboration Revenue74641Total Revenue13,58810100Gross Margin84%-R&D expense(3,159)1523-SG&A expense(4,492)333Total operating expense1(7,786)757Other operating income and expense113711Operating profit3,6741

24、727Tax rate14%Reported EPS$1.883211Q1 2025 Core profit and lossQ1 2025$mCER change%TotalRevenue-Product Sales12,875995-Alliance Revenue639425Product Revenue13,5141099-Collaboration Revenue74641Total Revenue13,58810100Gross Margin84%-R&D expense(3,088)1623-SG&A expense(3,457)425Total operating expens

25、e1(6,677)949Other operating income and expense115781Operating profit4,8031235Tax rate16%Core EPS$2.4921Due to rounding,the sum of a number of dollar values and percentages may not agree to totals.Absolute values at actual exchange rates;changes at CER.1.Total operating expense includes distribution,

26、R&D and SG&A expenses.Appendix:Glossary.12FY 2025 guidance reiteratedNet cash inflow from operating activities increased by 49%in Q1 2025Net debt/Adjusted EBITDA 1.5xFY 2025 guidance(CER)Total Revenueanticipated to increase by a high single-digit percentageCore EPSanticipated to increase by a low do

27、uble-digit percentage$bnNet debt end 202424.6CFO3.7CapEx10.5Deal payments and receipts20.8Dividend3.3Net debtend March 202526.1Other30.5$16.7bn$17.3bnAdjusted EBITDA4Due to rounding,the sum of a number of dollar values and percentages may not agree to totals.1.Capital expenditure on tangible assets

28、and software-related intangible assets.2.Comprises purchase and disposal of intangible assets(excluding software-related assets,including AZ Forest),movement in profit participation liability,purchase and disposal of non-current asset investments,payments to associates and joint ventures,disposal of

29、 investments in associates and joint ventures,acquisitions of subsidiaries,net of acquired net debt and payment of contingent consideration on business combinations.The Company uses Debt issuance to finance new Business Development opportunities.3.Comprises mainly Own shares purchased by Employee Be

30、nefit Trust.4.Rolling 12m EBITDA.AstraZeneca credit ratings:Moodys:short-term rating P-1,long-term rating A1,outlook stable.S&P Global Ratings:short-term rating A-1,long-term rating A+,outlook stable.5.If foreign exchange rates for April 2025 to December 2025 were to remain at the average rates seen

31、 in March 2025.Appendix:Glossary.Core tax rate expected to be between 18-22%Anticipated FX impact low single-digit adverse impact on Total Revenue and Core EPS5OncologyDave FredricksonONCOLOGY HAEMATOLOGY BUSINESSSusan GalbraithONCOLOGY HAEMATOLOGY R&D13Collaboration partners:Daiichi Sankyo(Enhertu,

32、Datroway),Merck&Co.,Inc.(Lynparza).1.Others is inclusive of Datroway.Appendix:Glossary.14Oncology Q1 2025Strong demand across key regions,partly offset by oral oncolytics Part D redesign in US Q1 2025:key dynamics Tagrisso Imfinzi+Imjudo Calquence Enhertu Truqap Lynparza(PR)Lynparza(CR)Others1Oncolo

33、gyQ1 2025$5.6bn,+13%Tagrisso+8%,increasing demand across indications,strong LAURA launch uptake Calquence+8%,continued BTKi leadership in CLL across major markets Lynparza PR+5%,sustained PARPi leadership Truqap$132m,market leadership in 2L biomarker-altered,partly impacted by one-time blister pack

34、destocking in US Imfinzi+16%,strong demand growth,continued JP repricing impact Imjudo+33%,durable HIMALAYA demand across major markets Enhertu+34%,strong demand in CN post-NRDL inclusion,DESTINY-Breast06 launch Datroway$4m,positive early launch signals in HR+/HER2-breast Key regulatory approvals:US

35、(Imfinzi NIAGARA),EU(Imfinzi ADRIATIC,Enhertu DESTINY-Breast06,Imfinzi AEGEAN)01,0002,0003,0004,0005,0006,0007,000Q2Q3Q4Q1Q2Q3Q4Q1202320242025Total Revenue($m)1.Co-developed with Roche Tissue Diagnostics.Collaboration partners:Daiichi Sankyo(Enhertu,Datroway).Appendix:Glossary.15camizestrantSERENA-6

36、MATTERHORNDESTINY-Breast09Oncology strong catalyst flow in Q1 2025 Positive key Phase III readouts reinforce leadership in breast and GI cancersAI+CDK4/6i switch to cami+CDK4/6i1L ESR1m HR+/HER2-mBC+FLOTperioperative gastric/GEJ cancer+pertuzumab1L HER2+mBC Highly significant and clinically meaningf

37、ul PFS improvement Trend in PFS2 improvement10k eligible patients across G723k eligible patients across G7 Significant and clinically meaningful EFS improvement Strong trend to OS improvement43k eligible patients across G7 Highly significant and clinically meaningful PFS improvement Early trend to O

38、S improvementFirst positive oral SERD Phase III in 1LBuilds on AEGEAN and NIAGARA perioperative successMoves Enhertu earlier in HER2+mBCASCO plenaryASCO plenaryUS Breakthrough Device Designation granted for TROP2-NMR companion diagnostic1 in 2L Datroway TROPION-Lung17 trialGaillard S et al.Abstract

39、933087 presented at 2025 SGO Annual Meeting on Womens Cancer 2025.Appendix:Glossary.16Oncology advancing transformative technologies Progress with in-house ADCs at Society of Gynecologic Oncology 2025IIIPhase IIIPhase I/IIPhase I/IIPhase IPhase I/IIPhase I/IIP-SamB7H4AZD5335FRAZD9592EGFR/cMETAZD0901

40、Cldn18.2AZD0305GPRC5DAZD9829CD123 Promising ORR 34.6-38.5%Preliminary 7.0 months mPFSNo TRAEs leading to discontinuationLow rates of haematologic toxicityEncouraging puxitatug samrotecan Phase I/IIa data in endometrial cancerB7H4TOP1iInitiating Phase III in endometrial cancer in 2025BioPharmaceutica

41、lsRuud DobberBIOPHARMACEUTICALS BUSINESSSharon BarrBIOPHARMACEUTICALS R&D17Appendix:Glossary.18BioPharmaceuticals Q1 2025Total Revenue$5.6bn,+12%,strong demand growth in expanding classes of medicinesCVRMQ1 2025$3.3bn,+13%R&IQ1 2025$2.1bn,+13%Q1 2025:key dynamics Farxiga+17%,global demand growth mai

42、nly driven by CKD and HF Lokelma+38%,market leader in growing class Brilinta(4%),generic competition ex-US Fasenra+19%,sustained IL-5 leadership and EGPA launch Tezspire+85%,continued launch momentum Breztri+39%,fastest growing medicine in expanding FDC triple class Saphnelo+51%,increasing penetrati

43、on in i.v.segment V&I(1%),Beyfortus 2x Total Revenue Farxiga Brilinta Lokelma OtherFasenra Breztri Tezspire Saphnelo Symbicort Other05001,0001,5002,0002,500Q2Q3Q4Q1Q2Q3Q4Q1202320242025Total Revenue($m)05001,0001,5002,0002,5003,0003,500Q2Q3Q4Q1Q2Q3Q4Q1202320242025Total Revenue($m)Key regulatory appro

44、vals:EU(Wainzua NEURO-TTRansform)1.Koren M et al.Abstract featured in Clinical Research V|Session 113 at American College of Cardiology Annual Scientific Session 2025.2.Koren MJ et al.J Am Coll Cardiol.2025 Mar 27:S0735-1097(25)05907-8.3.With once-daily AZD0780(30mg)taken in addition to standard-of-

45、care statins,LDL-C reduction 95%CI:-59.0%,-42.4%,p2026DGFAWAKE|InitiatingFDA BTDCEO Closing RemarksPascal SoriotCHIEF EXECUTIVE OFFICER231.risk-adjusted peak year revenue.Collaboration partner:Daiichi Sankyo(Enhertu,Datroway).Appendix:Glossary.242025 key Phase III readouts represent$10bn opportunity

46、1H2 2025CAEL-101/2anselamimablight chain amyloidosisHICKORY/CHESTNUTefzimfotase alfaHPPBaxHTNbaxdrostatuncontrolled or resistant hypertensionALXN1720-MG-301gefurulimabgMGLATIFYceralasertibPost-IO NSCLCAVANZARDatroway+Imfinzi1L NSCLCVOLGAImfinzicis-ineligible/refuse MIBCRESOLUTEFasenraCOPDH1 2025SERE

47、NA-6camizestrant1L ESR1m HR+/HER2-breast cancerDESTINY-Breast09Enhertu1L HER2+breast cancerDESTINY-Breast11Enhertuearly-stage HER2+breastKALOS/LOGOSBreztriuncontrolled asthmaCALYPSOeneboparatidehypoparathyroidismFirst Phase III data for 7 NMEsKey indication expansion opportunitiesTROPION-Breast02Dat

48、roway1L TNBCTMA-313Ultomirisadult HSCT-TMADESTINY-Breast05Enhertuearly-stage HER2+breastPOTOMACImfinziNMIBC25On track to deliver on 2030 ambitions supported by strong growth and pipeline momentumAmbition to deliver$80bn in Total Revenue by 20301On track to deliver mid-30s%Core operating margin by 20

49、26Ambition to deliver at least 20 NMEs by 2030The Financial Ambition Statements in this presentation are based on Q1 2024 exchange rates.1.2030 Total Revenue ambition is risk-adjusted and not dependent upon future M&A.Appendix:Glossary.Strong growth in 2025 with global medicines demand substantially

50、 offsetting anticipated headwindsGrowth in SG&A slower than Total RevenueR&D to remain low 20%s of Total Revenue9 NMEs launched to dateQ&A SessionPascal SoriotCHIEF EXECUTIVE OFFICERAradhana SarinCHIEF FINANCIAL OFFICERMarc DunoyerCHIEF EXECUTIVE OFFICER,ALEXIONSusan GalbraithEVP,ONCOLOGY HAEMATOLOG

51、Y R&DDave FredricksonEVP,ONCOLOGY HAEMATOLOGY BUSINESSSharon BarrEVP,BIOPHARMACEUTICALS R&DRuud DobberEVP,BIOPHARMACEUTICALS BUSINESSIskra ReicEVP,INTERNATIONALAppendix1.Partnered medicines include:Enhertu,Lynparza,Datroway,Beyfortus,Tezspire.Core financial measures are adjusted to exclude certain i

52、tems.The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles,impairments,legal settlements and restructuring charges.Appendix:Glossary.28Appendix AstraZeneca P&L reference tableP&L line-item definitionsP&L line-item definitionProduct

53、Sales Recognises sales from territories where Group has lead commercialisation Recognises supply of Beyfortus to SanofiAlliance Revenue Alliance Revenue comprises income arising from the ongoing operation of collaborative arrangements related to sales made by collaboration partners,where AstraZeneca

54、 is entitled to a share of gross profits,share of revenues or royalties,which are recurring in nature while the collaboration agreement remains in place1Product Revenue The sum of Product Sales and Alliance RevenueCollaboration Revenue Recognises any development or sales-based milestone received on

55、partnered medicines as well as any upfront payments associated with business development where AstraZeneca retains a significant ongoing economic interest in the product Total Revenue Sum of Product Sales,Alliance Revenue and Collaboration RevenueGross Margin Calculated by dividing Gross Profit by T

56、otal RevenueOther operating income&expense Other operating income and expense is generated from activities outside of the Groups normal course of business,which includes Other income from divestments of or full out-license of assets and businesses including royalties and milestones where the Group d

57、oes not retain a significant continued interestCore Operating margin Defined as Core Operating profit as a percentage of Total RevenueLung Cancer map reflects ongoing active Phase III trials.Collaboration partners:Daiichi Sankyo(Enhertu,Datroway),Compugen(rilvegostomig).Appendix:Glossary.29APPENDIX|

58、Oncology tumour mapsTagrisso ADAURAEGFRm16-19%IO sensitive70%Stg.IMetastatic1L2LEst.epi(G7,2025)150K310K190KHER2m 2%Other tumour drivers12%50K100KStg.I-IIStg.IIIUnresectableResectableImfinzi AEGEANTagrisso neoADAURArilvegostomig DatrowayTROPION-Lung12SBRT Imfinzi /TagrissoPACIFIC-4Imfinzi combos PAC

59、IFIC-8,-9 improvements across PD-L1 spectrumCRT TagrissoLAURACRT Imfinzi PACIFICCRT Imfinzi PACIFICEnhertuDESTINY-Lung04Imfinzi+Imjudo+CTx POSEIDONTagrisso FLAURADatroway+IO platinum TL08/TL07/AVANZARvolrustomig+CTx eVOLVE-Lung02rilvegostomig Datroway TROPION-Lung10Tagrisso+CTxFLAURA-2Datroway+Tagri

60、ssoTROPION-Lung14Datroway+/-TagrissoTROPION-Lung15Imfinzi+ceralasertib LATIFYsavolitinib+Tagrisso SAFFRON/SAVANNAHAZD9592(EGFR/cMET ADC)EGRETEnhertuDESTINY-Lung02Stg.II-III70KTagrisso ADAURA23L+70KDatrowayTROPION-Lung05rilvegostomig+CTx PDL11 SQ ARTEMIDE-Lung02rilvegostomig+CTx PDL11 NSQ ARTEMIDE-Lu

61、ng03rilvegostomig PDL150 ARTEMIDE-Lung04established SoClaunched indicationAstraZeneca in Lung Cancer(NSCLC)Overview of commercial portfolio and pivotal trials Datroway TROPION-Lung17NSQ TROP2-NMR+30All numbers are approximate.Illustrative settings and populations,not to scale.Collaboration partners:

62、Daiichi Sankyo(Enhertu,Datroway),Merck&Co.,Inc.(Lynparza).Appendix:Glossary.APPENDIX|Oncology tumour mapsRECURRENCEgBRCAm5%of HR-positive15%of TNBCHER2-positive15-20%HR-positive65-75%TNBC10-15%Est.epi(G7,2025)540k135k100k75k60k1st line2nd line3rd line4th line+EarlyNeoadjuvantAdjuvantMetastaticCTx Ly

63、nparzaOlympiAEnhertu+THPDESTINY-Breast11NST residual disease Datroway ImfinziTROPION-Breast03CTx AI CDK4/6i 2-5 yrs camizestrantCAMBRIA-1Good outcomes with current SoC for low-risk patientsCTx camizestrant abemaciclibCAMBRIA-2NST residual disease EnhertuDESTINY-Breast05PD-L1-60%PD-L1+40%Datroway+Imf

64、inziTROPION-Breast04LynparzaOlympiADcamizestrant+palbociclibSERENA-4AI+CDK4/6i camizestrant+CDK4/6i SERENA-6 ESR1m 35%Enhertu pertuzumabDESTINY-Breast09DatrowayTROPION-Breast02Datroway+ImfinziTROPION-Breast05Truqap+Faslodex+CDK4/6iCAPItello292saruparib+camizestrantEvoPAR-Breast01tBRCAm,PALB2m 9%Enhe

65、rtuDESTINY-Breast03EnhertuDESTINY-Breast01/02DatrowayTROPION-Breast01EnhertuDESTINY-Breast06HER2-low(1+,2+)60%HER2-ultralow(0-1+)25%Truqap+FaslodexCAPItello291PIK3CA,AKT1,PTEN alt.40%HER2-low(1+,2+)35%PD-L1-60%DESTINY-Breast04HER2-low(1+,2+)35%EnhertuDESTINY-Breast04HER2-low(1+,2+)60%PD-L1+40%establ

66、ished SoClaunched indicationAstraZeneca in Breast CancerOverview of commercial portfolio and pivotal trials 31Appendix Significant progress with transformative technologies to drive 2030+growthADCs/RCs,next-gen IO and cell therapy/TCE progressed to Phase IIIWeight management and risk factorsEstablis

67、h and lead in new weight management paradigm Multiple Phase II dose optimisation trials ongoingAZD5004(oGLP-1)AZD6234(LAA)ADCs and RadioconjugatesReplace systemic chemotherapy and radiotherapySix ADCs in clinical development,including:AZD0901(CLDN18.2)in Phase IIIFPI-2265 Phase II initiated in pre-t

68、reated PSMA-positive mCRPCNext-gen IO bispecificsReplace existing PD-1/PD-L1 inhibitors9 Phase III trials with rilvegostomig and volrustomig initiatedFirst ADC combination data at ASCO 2025Cell therapy and T-cell engagersDevelop scalable cell therapies and T-cell engagers across therapy areasAZD0120

69、(BCMA/CD19)CAR-T Phase III planned in multiple myelomaAZD0486(CD19/CD3)Phase III initiated in 1L FLGene therapy and gene editingMake cure possible for a range of rare diseasesPreclinical and Phase I development ongoing across multiple platformssAAVy and AAV capsidTALEN technologyCollaboration partne

70、rs:Compugen(rilvegostomig).Appendix:Glossary.Due to rounding,the sum of a number of dollar values and percentages may not agree to totals.Collaboration partner:Merck&Co.,Inc.(Lynparza).Appendix:Glossary.32OncologyTagrisso8%growth at CER to$1,679m in Q1 2025Lynparza 5%growth at CER to$726m in Q1 2025

71、APPENDIX|Product Revenue PerformanceQ1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM444408409360488432446391519ERoW202218198163182191186201175Europe257284281299302327328344307US52158157759762365871476767802004006008001,0001,2001,4001,6001,800Product Revenue($m)Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM13714213113316715315518

72、0161ERoW687771655966626657Europe178187178191191206214220196US2683113223522883193473783120100200300400500600700800900Product Revenue($m)33OncologyAPPENDIX|Product Revenue PerformanceImfinzi 16%growth at CER to$1,261m in Q1 2025Imjudo33%growth at CER to$80m in Q1 2025Due to rounding,the sum of a numbe

73、r of dollar values and percentages may not agree to totals.Appendix:Glossary.Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM811018687129117120113142ERoW129201207213170183167167139Europe162171203207232227236253252US49154057057058262068072172802004006008001,0001,2001,400Product Revenue($m)Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242

74、025EM011344455ERoW42214121113121311Europe155588101011US3236403839494645530102030405060708090Product Revenue($m)Due to rounding,the sum of a number of dollar values and percentages may not agree to totals.Collaboration partner:Daiichi Sankyo(Enhertu).Appendix:Glossary.34OncologyAPPENDIX|Product Reven

75、ue PerformanceCalquence8%growth at CER to$762m in Q1 2025Enhertu34%growth at CER to$596m in Q1 2025Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM182428293936413754ERoW222730283233333131Europe108117128140153167169167170US3844854684784945545705735070100200300400500600700800900Product Revenue($m)Q1Q2Q3Q4Q1Q2Q3Q4Q120

76、2320242025EM38697274112112128125172ERoW359151319162219Europe55707991134129136142146US1611781791842022122292502580100200300400500600700Product Revenue($m)35BioPharmaceuticals:Cardiovascular,Renal&MetabolismAPPENDIX|Product Revenue PerformanceFarxiga16%growth at CER to$2,058m in Q1 2025Brilinta4%decre

77、ase at CER to$305m in Q1 2025Lokelma38%growth at CER to$153m in Q1 2025Due to rounding,the sum of a number of dollar values and percentages may not agree to totals.Appendix:Glossary.Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM498578577559711763750628871ERoW11413510472109104108103121Europe39345650652555368067073

78、1683US29633936645147339441147238305001,0001,5002,0002,500Product Revenue($m)Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM827964618878666274ERoW666654563Europe676868686769676555US179178193194163191189208173050100150200250300350400Product Revenue($m)Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM111313132121261830ERoW20242224232

79、8263128Europe111416171823252626US564951585264667569020406080100120140160180Product Revenue($m)36BioPharmaceuticals:Respiratory&ImmunologyAPPENDIX|Product Revenue PerformanceFasenra19%growth at CER to$418m in Q1 2025Tezspire85%growth at CER to$217m in Q1 2025Saphnelo51%growth at CER to$136m in Q1 202

80、5Due to rounding,the sum of a number of dollar values and percentages may not agree to totals.Collaboration partner:Amgen(Tezspire).Appendix:Glossary.Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM141419162219272327ERoW353635363337363939Europe888986939399102110103US2012672492752102682712992490501001502002503003504

81、00450500Product Revenue($m)Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM000123347ERoW4810141419222523Europe71111172735435157US4362748377104123133130050100150200250Product Revenue($m)Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM010111323ERoW223334454Europe112346799US4464718283101110131120020406080100120140160Product Revenue($

82、m)37BioPharmaceuticals:Respiratory&ImmunologyAPPENDIX|Product Revenue PerformanceBreztri39%growth at CER to$300m in Q1 2025Symbicort3%decrease at CER to$723m in Q1 2025Due to rounding,the sum of a number of dollar values and percentages may not agree to totals.Appendix:Glossary.Q1Q2Q3Q4Q1Q2Q3Q4Q1202

83、320242025EM384342387061684590ERoW101512151419192120Europe152119263035374242US818498120105120142149148050100150200250300350Product Revenue($m)Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM229177195153253197203153232ERoW798681887583838877Europe147137123142142143130144135US2332001561372992992892992790100200300400500

84、600700800900Product Revenue($m)Due to rounding,the sum of a number of dollar values and percentages may not agree to totals.Appendix:Glossary.38Rare DiseaseAPPENDIX|Product Revenue PerformanceUltomiris25%growth at CER to$1,050m in Q1 2025Strensiq14%growth at CER to$352m in Q1 2025Koselugo8%growth at

85、 CER to$138m in Q1 2025Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM131717243235264952ERoW98110131138143152170173166Europe159152184173202209238235228US38143444549048255059763260402004006008001,0001,200Product Revenue($m)Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM159511211081534ERoW212221222223242726Europe212122252424252626

86、US205248237247246283286352266050100150200250300350400450Product Revenue($m)Q1Q2Q3Q4Q1Q2Q3Q4Q1202320242025EM241411105924256940ERoW367999101111Europe111215151826292934US414854514655555653020406080100120140160180Product Revenue($m)39Glossary1L,2L,3Lfirst-,second-,third-lineAAVadeno-associated virusACCA

87、merican College of CardiologyADCantibody-drug conjugateAHAAmerican Heart AssociationaHUSatypical haemolytic uraemic syndromeAIaromatase inhibitorAKT1AKT serine/threonine kinase 1B7H4B7 homolog 4BCMAB-cell maturation antigenBTKiBrutons tyrosine kinaseCAR-Tchimeric antigen receptor T-cellsCD123interle

88、ukin-3 receptor alpha chainCD19cluster of differentiation 19CD3cluster of differentiation 3CDK4/6icyclin-dependent kinase 4/6 inhibitorCERconstant exchange ratesCFOnet cash inflow from operating activitiesciscisplatinCKDchronic kidney diseaseCLDN18.2Claudin-18.2CLLchronic lymphocytic leukaemiacMETc-

89、mesenchymal epithelial transition factor CNChinaCOPDchronic obstructive pulmonary diseaseCRCollaboration RevenueCRTchemoradiotherapyCSA-AKIcardiac surgery-associated acute kidney injury CTxchemotherapyCVRMCardiovascular,Renal and MetabolismDato-DXdDatrowayDGFdelayed graft functionEBITDAearnings befo

90、re interest,tax,depreciation and amortisationEGFRepidermal growth factor receptorEGFRmepidermal growth factor receptor-mutantEPSearnings per shareERoWEstablished Rest of WorldESR1mestrogen receptor alpha-mutatedEUEuropeFDCfixed-dose combinationFLfollicular lymphomaFLOTluorouracil,leucovorin,oxalipla

91、tin and docetaxelFRfolate receptor alphaFXforeign exchangeG7US,Japan,EU5gBRCAmgermline BRCA-mutated breast cancerGCgastric cancerGEJgastroesophageal junctionGEJCgastroesophageal junction cancerGIgastrointestinalgMGgeneralised myasthenia gravisGPRC5DG protein-coupled receptor class C group 5 member D

92、HeFHheterozygous familial hypercholesterolemiaHER2-human epidermal growth factor receptor 2HER2+human epidermal growth factor receptor 2-positiveHER2-lowhuman epidermal growth factor receptor 2-lowHER2-ultralowhuman epidermal growth factor receptor 2-ultralowHFheart failureHPPhypophosphatasiaHR+horm

93、one receptor positiveHSCThematopoietic stem cell transplantationHSCT-TMAhematopoietic stem cell transplantation-associated thrombotic microangiopathyi.v.intravenousIgANIgA nephropathyIL-5interleukin-5IOimmuno-oncologyJPJapanLAAlong-acting amylinLDHlactate dehydrogenaseLDL-Clow-density lipoprotein ch

94、olesterolmBCmetastatic breast cancermCRPCmetastatic castration-resistant prostate cancerMIBCmuscle-invasive bladder cancermPFSmedian progression-free survivalNMEnew molecular entityNMIBCnon-muscle invasive bladder cancer NMRnormalised membrane ratioNRDLnational reimbursement drug listNSCLCnon-small

95、cell lung cancerNSQnon-squamous NSTneoadjuvant systemic treatmentoGLP-1oral glucagon-like peptide-1oPCSK9oral protein convertase subtilisin/kexin type 9ORRoverall response rate OSoverall survivalP&LProfit&LossPALB2mpartner and localizer of BRCA2PARPipoly-ADP ribose polymerase inhibitorPCSK9protein c

96、onvertase subtilisin/kexin type 9PD-1programmed cell death protein-1PDL1programmed death-ligand 1PD-L1programmed cell death ligand 1PFSprogression free survivalPIK3CAphosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunitPNHparoxysmal nocturnal haemoglobinuriaPSProduct SalesPSMAprostate-spec

97、ific membrane antigenPTENphosphatase and TENsin homolog deleted on chromosome 10PYRPeak-Year RevenueR&DResearch&DevelopmentR&IRespiratory&ImmunologyRCradioconjugateSERDselective estrogen receptor degraderSG&ASelling,General&AdministrativeSoCstandard-of-careSQsquamousStg.stagetBRCAmtumor BRCA mutatio

98、nTCET-cell engagerTHPdocetaxel,trastuzumab and pertuzumabTL07TROPION-Lung07TL08TROPION-Lung08TNBCtriple negative breast cancerTRAEtreatment-related adverse eventTROP2trophoblast cell surface antigen 2UKUnited KingdomUSUnited StatesV&IVaccines&Immune TherapiesConfidentiality NoticeThis file is privat

99、e and may contain confidential and proprietary information.If you have received this file in error,please notify us and remove it from your system and note that you must not copy,distribute or take any action in reliance on it.Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful.AstraZeneca PLC,1 Francis Crick Avenue,Cambridge Biomedical Campus,Cambridge,CB2 0AA,UK+44(0)203 749 40